Salim Abou Jaoude, MD
Pulmonary Disease · Lafayette, INNPI 1043280670
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,876 of the $50,879 with a category attached, or 66.6%. 24 manufacturers reported payments, led by Mylan Specialty L.p. at 37.0% of the total. Reporting peaked in 2019 at $26,835 and has fallen 98.1% since, to $499 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $246.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$19K
- Sunovion Pharmaceuticals Inc.$14K
- Boehringer Ingelheim$13K
- Intuitive Surgical$4K
- AstraZeneca$720
- GSK$188
- plus $887 from 18 others
What the payments were for
- Consulting fees$3,9558%
- Speaking & faculty fees$33,87667%
- Travel & lodging$5,65911%
- Food & beverage$4,2668%
- Education$3,1236%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 45 | $18,840 |
| Sunovion Pharmaceuticals Inc. | 55 | $13,536 |
| Boehringer Ingelheim | 29 | $12,515 |
| Intuitive Surgical | 11 | $4,193 |
| AstraZeneca | 23 | $720 |
| GSK | 8 | $188 |
| Inspire Medical Systems, Inc. | 2 | $137 |
| Harmony Biosciences LLC | 4 | $136 |
| Jazz Pharmaceuticals Inc. | 3 | $97 |
| United Therapeutics Corporation | 4 | $81 |
| Grifols USA, LLC | 2 | $69 |
| Actelion Pharmaceuticals US, Inc. | 1 | $56 |
| Merck | 4 | $55 |
| Sanofi | 2 | $52 |
| Philips North America LLC | 2 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Electromed, Inc. | 2 | $28 |
| Circassia Inc. | 1 | $19 |
| Resmed Corp | 1 | $18 |
| Olympus America Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Boston Scientific | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$17,939
- LONHALA MAGNAIR$12,742
- Da Vinci Surgical System$3,930
- BREZTRI$125
- TEZSPIRE$125
- SYMBICORT$125
- NUCALA$108
- Wakix$106
How this compares
$50,879 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 499 | $378,201 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 417 | $328,863 |
| OpsumitMacitentan | 17 | $213,487 |
| OfevNintedanib Esylate | 11 | $143,270 |
| LetairisAmbrisentan | 11 | $143,026 |
| Orenitram ErTreprostinil Diolamine | 11 | $141,615 |
| Breo ElliptaFluticasone/Vilanterol | 214 | $109,702 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 154 | $90,561 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 133 | $87,064 |
| Spiriva RespimatTiotropium Bromide | 105 | $69,633 |
| SymbicortBudesonide/Formoterol Fumarate | 217 | $61,710 |
| Dupixent PenDupilumab | 11 | $40,049 |
| Ambrisentan | 15 | $32,133 |
| EliquisApixaban | 31 | $29,296 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 970 | $23,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $188 | $597,736914 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $720 | $405,336666 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $12,515 | $312,843272 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $56 | $213,48717 claims |
| GileadLetairis | $11 | $143,02611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Lafayette
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
- Gaurav KumarPortage$102K
- Rajeev MehtaMuncie$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.